Share Buyback2026-07-22

Finemedix to acquire treasury shares via trust

FIN

파인메딕스

387570

+0.15

Signal Score

53CNeutral
Score53 / 100

Historical Avg Return (5d)

+0.44%

Data Coverage

100%n=372

Risk-adjusted indicator based on 372 historical DART filings. For informational purposes only — not investment advice.

Financial Impact

NEUTRAL

Capital Return

Share Buyback

Open market share repurchase

Shareholder Impact

Positive

Key Numbers

  • • Board Resolution Date: July 22, 2026
  • • Listing Date: December 26, 2024 (KOSDAQ)
  • • Treasury Shares (Pre-listing): 195,500 Shares
  • • Treasury Shares for ESOP: 72,000 Shares
  • • Treasury Shares for Exchangeable Bonds: 123,500 Shares

AI Analysis Summary

Finemedix Co., Ltd. has decided to enter into a treasury stock acquisition trust agreement, with the board resolution dated July 22, 2026. The company was listed on KOSDAQ on December 26, 2024. Prior to listing, Finemedix held 195,500 treasury shares, of which 72,000 shares were for employee stock options and 123,500 shares were designated for exchangeable bonds issued on December 30, 2025. The actual acquisition quantity and price will vary based on market conditions. This move is generally positive for shareholder value by reducing outstanding shares, but the specific financial impact is currently neutral as the contract amount and target shares are not yet disclosed.

How This Event Is Evaluated

Share Buyback Evaluation

Share buyback events are evaluated by assessing capital return size, share supply reduction, execution method, and cancellation intent.

AI is used to interpret disclosures and extract structured data.

Signal scores are generated using event-specific methodologies and quantitative models.

  • Buyback size relative to market value
  • Share count impact
  • Acquisition period and method
  • Cancellation or retirement plan
Read our full scoring methodology →

This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.

AI-processed analysis. Based on: 주요사항보고서(자기주식취득신탁계약체결결정). Source: Financial Supervisory Service (금융감독원 전자공시시스템). Raw government data is not redistributed. Not investment advice.